128 related articles for article (PubMed ID: 18425390)
1. Alterations of the K-ras and p53 genes in Tamoxifen-associated endometrial carcinoma.
Fujiwara K; Enomoto T; Fujita M; Kanda T; Fujii S; Ito K; Wakasa K; Ishiko O; Ueda M; Yamaguchi S; Kimura T; Umesaki N
Oncol Rep; 2008 May; 19(5):1293-8. PubMed ID: 18425390
[TBL] [Abstract][Full Text] [Related]
2. K-ras mutation in tamoxifen-related endometrial polyps.
Hachisuga T; Miyakawa T; Tsujioka H; Horiuchi S; Emoto M; Kawarabayashi T
Cancer; 2003 Nov; 98(9):1890-7. PubMed ID: 14584071
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma.
Ferguson SE; Olshen AB; Viale A; Awtrey CS; Barakat RR; Boyd J
Gynecol Oncol; 2004 Feb; 92(2):719-25. PubMed ID: 14766275
[TBL] [Abstract][Full Text] [Related]
4. [Tamoxifen and giant endometrial polyps].
Caschetto S; Cassaro N; Consalvo P; Caragliano L
Minerva Ginecol; 2000 Nov; 52(11):459-63. PubMed ID: 11256174
[TBL] [Abstract][Full Text] [Related]
5. A comparative analysis of Ki-67, p53, and p21WAF1CIP1 expression in tamoxifen associated endometrial carcinomas.
Ramondetta LM; Palazzo JP; Dunton CJ; Kovatich AJ; Carlson JA
Anticancer Res; 1998; 18(6B):4661-5. PubMed ID: 9891537
[TBL] [Abstract][Full Text] [Related]
6. A case-case analysis of factors related to overexpression of p53 in endometrial cancer following breast cancer.
Olson SH; Finstad CL; Harlap S; Kurian L; Saigo PE; Barakat RR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):815-7. PubMed ID: 9332764
[TBL] [Abstract][Full Text] [Related]
7. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.
Tergas AI; Buell-Gutbrod R; Gwin K; Kocherginsky M; Temkin SM; Fefferman A; Lengyel E; Yamada SD
Gynecol Oncol; 2012 Nov; 127(2):316-20. PubMed ID: 22835717
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.
Tsujioka H; Hachisuga T; Fukuoka M; Ueda T; Miyahara D; Horiuchi S; Shirota K; Yoshizato T; Emoto M; Miyamoto S; Kawarabayashi T
Int J Gynecol Cancer; 2009 Aug; 19(6):1052-6. PubMed ID: 19820367
[TBL] [Abstract][Full Text] [Related]
9. [Endometrial cancers arising in polyps associated with tamoxifen use].
Mbatsogo BA; Le Bouëdec G; Michy T; Bourdel N; Fouilloux G; Dauplat J
Gynecol Obstet Fertil; 2005 Dec; 33(12):975-9. PubMed ID: 16321556
[TBL] [Abstract][Full Text] [Related]
10. Metastatic breast lobular carcinoma involving tamoxifen-associated endometrial polyps: report of two cases and review of tamoxifen-associated polypoid uterine lesions.
Houghton JP; Ioffe OB; Silverberg SG; McGrady B; McCluggage WG
Mod Pathol; 2003 Apr; 16(4):395-8. PubMed ID: 12692205
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations.
Tsujioka H; Hachisuga T; Hikita S; Ueda T; Yotsumoto F; Shirota K; Yoshizato T; Kawarabayashi T; Kuroki M; Miyamoto S
Anticancer Res; 2010 Aug; 30(8):3119-23. PubMed ID: 20871029
[TBL] [Abstract][Full Text] [Related]
12. Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells.
Besaratinia A; Pfeifer GP
Biochemistry; 2005 Jun; 44(23):8418-27. PubMed ID: 15938631
[TBL] [Abstract][Full Text] [Related]
13. Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen.
Strissel PL; Ellmann S; Loprich E; Thiel F; Fasching PA; Stiegler E; Hartmann A; Beckmann MW; Strick R
Int J Cancer; 2008 Dec; 123(12):2871-9. PubMed ID: 18814240
[TBL] [Abstract][Full Text] [Related]
14. [Histological analysis of endometrial polyps in breast cancer patients treated with tamoxifen (nolvadex)].
Ivanova V; Karaivanov M; Raĭcheva S; Marinov E; Gorchev G
Akush Ginekol (Sofiia); 2004; 43(2):33-6. PubMed ID: 15185527
[TBL] [Abstract][Full Text] [Related]
15. Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.
Yasue A; Hasegawa K; Udagawa Y
Hum Cell; 2011 Jun; 24(2):65-73. PubMed ID: 21547354
[TBL] [Abstract][Full Text] [Related]
16. Differences in K-ras and p53 gene mutations among pancreatic adenocarcinomas associated with regional environmental pollution.
Soliman AS; Lo AC; Banerjee M; El-Ghawalby N; Khaled HM; Bayoumi S; Seifeldin IA; Abdel-Aziz A; Abbruzzese JL; Greenson JK; Hamilton SR
Carcinogenesis; 2007 Aug; 28(8):1794-9. PubMed ID: 17575320
[TBL] [Abstract][Full Text] [Related]
17. Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma.
Sasaki H; Nishii H; Takahashi H; Tada A; Furusato M; Terashima Y; Siegal GP; Parker SL; Kohler MF; Berchuck A
Cancer Res; 1993 Apr; 53(8):1906-10. PubMed ID: 8467512
[TBL] [Abstract][Full Text] [Related]
18. Random nuclear p53 overexpression pattern in tamoxifen-mediated endometrial carcinoma.
Kuwashima Y; Kurosumi M; Kobayashi Y; Tanuma J; Suemasu K; Higashi Y; Kasamatsu T; Shiromizu K; Kishi K
Int J Gynecol Pathol; 1998 Apr; 17(2):135-9. PubMed ID: 9553810
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen (TAM): the dispute goes on.
Grilli S
Ann Ist Super Sanita; 2006; 42(2):170-3. PubMed ID: 17033137
[TBL] [Abstract][Full Text] [Related]
20. Endometrial carcinoma following treatment for breast carcinoma in a Nigerian female. A case report and review of the literature.
Abudu EK; Musa O; Adefuye PO; Abdul Kareem FB; Agboola AO; Banjo AA
Niger Postgrad Med J; 2007 Dec; 14(4):355-7. PubMed ID: 18163149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
